BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28668896)

  • 1. Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
    Kanemura Y; Sumida M; Okita Y; Yoshioka E; Yamamoto A; Kanematsu D; Handa Y; Fukusumi H; Inazawa Y; Takada AI; Nonaka M; Nakajima S; Mori K; Goto S; Kamigaki T; Shofuda T; Moriuchi S; Yamasaki M
    Anticancer Res; 2017 Jul; 37(7):3921-3932. PubMed ID: 28668896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
    Ishikawa E; Yamamoto T; Sakamoto N; Nakai K; Akutsu H; Tsuboi K; Takano S; Matsumura A
    Neurol Med Chir (Tokyo); 2010; 50(8):638-44. PubMed ID: 20805645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of temozolomide on immune response during malignant glioma chemotherapy.
    Sengupta S; Marrinan J; Frishman C; Sampath P
    Clin Dev Immunol; 2012; 2012():831090. PubMed ID: 23133490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
    Sanchez-Perez LA; Choi BD; Archer GE; Cui X; Flores C; Johnson LA; Schmittling RJ; Snyder D; Herndon JE; Bigner DD; Mitchell DA; Sampson JH
    PLoS One; 2013; 8(3):e59082. PubMed ID: 23527092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
    Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
    Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
    Dai B; Qi N; Li J; Zhang G
    Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.
    Fritzell S; Sandén E; Eberstål S; Visse E; Darabi A; Siesjö P
    Cancer Immunol Immunother; 2013 Sep; 62(9):1463-74. PubMed ID: 23775421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
    Chiba Y; Hashimoto N; Tsuboi A; Oka Y; Murao A; Kinoshita M; Kagawa N; Oji Y; Hosen N; Nishida S; Sugiyama H; Yoshimine T
    Jpn J Clin Oncol; 2010 May; 40(5):395-403. PubMed ID: 20364021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
    Gupta T; Mohanty S; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
    Huang J; DeWees TA; Badiyan SN; Speirs CK; Mullen DF; Fergus S; Tran DD; Linette G; Campian JL; Chicoine MR; Kim AH; Dunn G; Simpson JR; Robinson CG
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1000-1007. PubMed ID: 26025775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
    Mitchell DA; Cui X; Schmittling RJ; Sanchez-Perez L; Snyder DJ; Congdon KL; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
    Blood; 2011 Sep; 118(11):3003-12. PubMed ID: 21768296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
    Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
    Wen PY; Omuro A; Ahluwalia MS; Fathallah-Shaykh HM; Mohile N; Lager JJ; Laird AD; Tang J; Jiang J; Egile C; Cloughesy TF
    Neuro Oncol; 2015 Sep; 17(9):1275-83. PubMed ID: 26019185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
    Qian ZZ; Wang HQ; Liu XM; Yang SY; Fu Z; Chang Y; Liu XY; Yu H
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(29):2059-62. PubMed ID: 20017331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide in malignant gliomas: current use and future targets.
    Villano JL; Seery TE; Bressler LR
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
    Su YB; Sohn S; Krown SE; Livingston PO; Wolchok JD; Quinn C; Williams L; Foster T; Sepkowitz KA; Chapman PB
    J Clin Oncol; 2004 Feb; 22(4):610-6. PubMed ID: 14726505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
    Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK
    Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.